胃癌患者血清微小RNA30水平及其临床意义#br#
#br#

摘要/Abstract

摘要： 目的探讨胃癌患者的血清微小RNA30（miR30）水平并分析其与临床病理特征和预后的关系。
方法收集本院2014年3月至2017年5月108例胃癌患者的术前血清及同期100例健康体检者的血清样本，采用实时定量PCR（QPCR）检测以上样本的miR30水平，比较胃癌患者与健康体检者的miR30水平差异，以miR30水平的均值为界值分为低表达组（＜均值）和高表达组（≥均值），分析miR30水平与临床病理参数（性别、年龄、淋巴结转移、肿瘤大小、TNM分期、浸润深度、Lauren分型和分化程度）的关系，根据随访数据比较不同血清miR30水平的预后情况。
结果胃癌患者的血清miR30水平为0624±0075，低于对照组的1028±0094，差异有统计学意义（P＜005）。ROC曲线分析结果显示miR30诊断胃癌的曲线下面积为0802（95％CI：0742～0861，P＜0001），诊断阈值取0798时，敏感度和特异度分别为759％和760％。胃癌患者的血清miR30水平与性别、年龄、浸润深度和Lauren分型均无关（P＞005），而与淋巴结转移、肿瘤大小、TNM分期和分化程度有关（P＜005），其中淋巴结转移、肿瘤大小≥5 cm、TNM Ⅲ～Ⅳ期和低分化者的低表达率分别为632％（48／76）、726％（45／62）、923％（36／39）和681％（32／47），均高于淋巴结无转移、肿瘤大小＜5 cm、TNM Ⅰ～Ⅱ期和中高分化者的375％（12／32）、326％（15／46）、348％（24／69）和459％（28／61），差异有统计学意义（P＜005）。miR30低表达组的中位总生存期为230个月，短于高表达组的360个月，差异有统计学意义（P＜005）。
结论miR30在胃癌患者血清中低表达，参与胃癌的发生发展且低水平者的预后较差，具有作为胃癌筛查和预后预测标志物的潜能。

关键词: 胃癌, 微小RNA30, 临床意义, 预后

Abstract: ObjectiveTo investigate the serum microRNA30 （miR30） level in gastric cancer patients and analyze its relationship with clinicopathological features and prognosis.
MethodsThe serum samples of 108 patients with gastric cancer from March 2014 to May 2017 and 100 health examiners in the same period were collected， and the miR30 levels in the above samples were detected by realtime quantitative PCR （QPCR）. The difference of miR30 level between the patients with gastric cancer and the health examiners were compared. The values of the miR30 level were divided into the lowexpression group （＜average value） and the highexpression group （＞average value）. The relationship between miR30 level and clinicopathological parameters （gender， age， lymph node metastasis， tumor size， TNM staging， depth of infiltration， Lauren classification and differentiation） was analyzed， and the prognosis of different serum miR30 levels was compared according to the followup data.
ResultsThe serum miR30 level of gastric cancer patients was 0624±0075， lower than 1028±0094 of the control group， and the difference was statistically significant （P＜005）. The results of ROC curve analysis showed that the area under the curve of miR30 for diagnosis of gastric cancer was 0802 （95％CI： 07420861， P＜0001）. When the diagnostic threshold was 0798， the sensitivity was 759％ and the specificity was 76％. Serum miR30 levels in patients with gastric cancer were not related to sex， age， depth of infiltration and Lauren classification， but related to lymph node metastasis， tumor size， TNM staging and degree of differentiation （P＜005）. The low expression rates of patients with lymph node metastasis， tumor size more than 5 cm， TNM ⅢⅣ and low differentiation were 632％（48／76）， 726％（45／62）， 923％（36／39） and 681％（32／47）， higher than 375％（12／32）， 326％（15／46）， 348％（24／69） and 459％（28／61） of lymph nodes without metastasis， tumor size＜5 cm， TNM ⅠⅡ and middlehigh differentiation （P＜005）. The median overall survival of miR30 lowexpression group was 230 months， shorter than 360 months of highexpression group （P＜005）.
ConclusionMiR30 is lowly expressed in the serum of patients with gastric cancer， and is involved in the development of gastric cancer and the prognosis of patients with low serum miR30 level is poor. It has the potential as a molecular screening and prognostic marker for gastric cancer.

Key words: Gastric cancer, MicroRNA30, Clinical significance, Prognosis

徐彬, 杨高松. 胃癌患者血清微小RNA30水平及其临床意义#br# #br#[J]. 临床肿瘤学杂志, 2018, 23(8): 698-700.

XU Bin, YANG Gaosong. Analysis of serum microRNA30 level in patients with gastric cancer and its clinical significance[J]. Chinese Clinical Oncology, 2018, 23(8): 698-700.

参考文献

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed